Investing.com - Financial Markets Worldwide

Proteomics International Laboratories Ltd (PIQ)

Sydney
Currency in AUD
0.320
0.000(0.00%)
Closed·
PIQ Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PIQ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.3200.330
52 wk Range
0.2850.930
Key Statistics
Edit
Bid/Ask
0.33 / 0.33
Prev. Close
0.32
Open
0.325
Day's Range
0.32-0.33
52 wk Range
0.285-0.93
Volume
302.43K
Average Volume (3m)
367.6K
1-Year Change
-63.64%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PIQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
1.385
Upside
+332.81%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 9
RSI suggests the stock is in oversold territory
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Proteomics International Laboratories Ltd Company Profile

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.

Industry
Biotechnology & Medical Research
Sector
Healthcare
0
Market
Australia

Compare PIQ to Peers and Sector

Metrics to compare
PIQ
Peers
Sector
Relationship
P/E Ratio
−7.4x−1.2x−0.5x
PEG Ratio
−3.08−0.010.00
Price/Book
9.6x1.5x2.6x
Price / LTM Sales
15.0x3.7x3.3x
Upside (Analyst Target)
332.8%107.3%38.7%
Fair Value Upside
Unlock12.5%5.0%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 1.385
(+332.81% Upside)

Earnings

Latest Release
Feb 25, 2025
EPS / Forecast
-0.03 / --
Revenue / Forecast
837.38K / --
EPS Revisions
a
a
Unlock
Last 90 days

PIQ Income Statement

FAQ

What Stock Exchange Does Proteomics Intl Labs Trade On?

Proteomics Intl Labs is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Proteomics Intl Labs?

The stock symbol for Proteomics Intl Labs is "PIQ."

What Is the Proteomics Intl Labs Market Cap?

As of today, Proteomics Intl Labs market cap is 53.20M.

What Is Proteomics Intl Labs's Earnings Per Share (TTM)?

The Proteomics Intl Labs EPS (TTM) is -0.05.

From a Technical Analysis Perspective, Is PIQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Proteomics Intl Labs Stock Split?

Proteomics Intl Labs has split 0 times.

How Many Employees Does Proteomics Intl Labs Have?

Proteomics Intl Labs has 0 employees.

What is the current trading status of Proteomics Intl Labs (PIQ)?

As of 27 Aug 2025, Proteomics Intl Labs (PIQ) is trading at a price of 0.32, with a previous close of 0.32. The stock has fluctuated within a day range of 0.32 to 0.33, while its 52-week range spans from 0.29 to 0.93.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.